HC Wainwright Reiterates Hold Rating for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Share on StockTwits

Sunesis Pharmaceuticals (NASDAQ:SNSS)‘s stock had its “hold” rating reissued by analysts at HC Wainwright in a report released on Wednesday, AnalystRatings.com reports.

A number of other equities research analysts have also recently weighed in on SNSS. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $2.67.

Sunesis Pharmaceuticals stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.37. The company’s stock had a trading volume of 751,900 shares, compared to its average volume of 1,003,336. The stock has a market cap of $43.53 million, a price-to-earnings ratio of -0.49 and a beta of 2.87. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.56 and a quick ratio of 2.27. Sunesis Pharmaceuticals has a 12 month low of $0.20 and a 12 month high of $1.77. The business has a 50 day moving average price of $0.60 and a 200-day moving average price of $0.82.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.04. On average, equities research analysts expect that Sunesis Pharmaceuticals will post -0.32 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. purchased a new stake in Sunesis Pharmaceuticals in the second quarter worth about $1,018,000. Algert Global LLC grew its holdings in shares of Sunesis Pharmaceuticals by 226.1% during the second quarter. Algert Global LLC now owns 67,014 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 46,464 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Sunesis Pharmaceuticals by 228.0% during the second quarter. Vanguard Group Inc. now owns 2,283,383 shares of the biopharmaceutical company’s stock valued at $1,660,000 after buying an additional 1,587,157 shares during the last quarter. A.R.T. Advisors LLC grew its holdings in shares of Sunesis Pharmaceuticals by 33.9% during the second quarter. A.R.T. Advisors LLC now owns 98,842 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 25,042 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Sunesis Pharmaceuticals by 257.3% during the second quarter. BlackRock Inc. now owns 783,059 shares of the biopharmaceutical company’s stock valued at $569,000 after buying an additional 563,924 shares during the last quarter. Institutional investors and hedge funds own 32.88% of the company’s stock.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Article: What are the benefits of investing in REITs?

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.